French biotech company MedinCell, tracked prior by TrialSite for its research into ivermectin, recently reported on the results of a comprehensive safety test evidencing that the drug ivermectin is safe. Based on the analysis, the company declared there are no safety concerns anticipated that would preclude health authority review as a new indication for COVID-19. Authorized by a prominent toxicologist, the study included an extensive analysis of over 350 articles and reports from various medical and scientific journals. The company will submit the analysis for peer review to an internally acknowledged journal.
The study was conducted by Pr. Jacques Descotes, MD, PharmD, PhD, Professor Emeritus, Claude Bernard University of Lyon, a world-renowned toxicologist with a 40-year track record working both with pharmaceutical companies as well as with regulatory bodies around the world.
Administered to ‘Hundreds of Millions of People’
Dr. Descotes recently went on the record for the MedinCell press release: “Ivermectin has been administered orally to hundreds so millions of people throughout the world in the past three decades. The assessment of reported adverse e...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).